drug-repurposing
(2)
Andrew Reaume
Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.
Richard Novak
Richard Novak is a bioengineer and entrepreneur who co-founded and leads Unravel Biosciences, a rare disease therapeutics company built on its BioNAV platform that uses RNA network analysis to ask whether a drug will help real patients before working backward to find its target. A former lead engineer at Harvard's Wyss Institute with 15+ years in drug discovery systems, he also founded the swab company Rhinostics during the COVID-19 pandemic and the science-education nonprofit Future Scientist. Novak holds a PhD in Bioengineering from UC Berkeley and a BS in Biology from Emory, and is a 2024 Termeer Fellow.